In this investigation, genomic ascertainment of two population-based, exome-sequenced, HER-linked cohorts were used to quantify Bonferroni-corrected risk of cancers arising from adults harboring P/LP germline variants in non-NF1 RASopathy genes. This evidence concerns the gene NF1 and RASopathy.